Subscribe
intellectual-property
Jirsak / shutterstock.com
18 August 2016Americas

Janssen Remicade patent invalidated in Massachusetts

The US District Court for the District of Massachusetts has issued a ruling on a summary judgment motion filed by Celltrion Healthcare and Hospira, invalidating a Janssen patent related to Remicade (infliximab).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Pfizer to launch second-ever biosimilar in the US
18 October 2016   Pfizer announced yesterday that it will launch a biosimilar of one of Johnson & Johnson’s (J&J) best-selling drugs, Remicade (infliximab), which brought in a total of $9.2 billion in revenue last year.
Americas
Janssen drops biosimilar suit against Samsung
15 November 2017   Janssen, a subsidiary of Johnson & Johnson, has dropped a lawsuit against Samsung's biopharmaceutical arm Samsung Bioepis.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Americas
Pfizer to launch second-ever biosimilar in the US
18 October 2016   Pfizer announced yesterday that it will launch a biosimilar of one of Johnson & Johnson’s (J&J) best-selling drugs, Remicade (infliximab), which brought in a total of $9.2 billion in revenue last year.
Americas
Janssen drops biosimilar suit against Samsung
15 November 2017   Janssen, a subsidiary of Johnson & Johnson, has dropped a lawsuit against Samsung's biopharmaceutical arm Samsung Bioepis.

More on this story

Americas
Pfizer to launch second-ever biosimilar in the US
18 October 2016   Pfizer announced yesterday that it will launch a biosimilar of one of Johnson & Johnson’s (J&J) best-selling drugs, Remicade (infliximab), which brought in a total of $9.2 billion in revenue last year.
Americas
Janssen drops biosimilar suit against Samsung
15 November 2017   Janssen, a subsidiary of Johnson & Johnson, has dropped a lawsuit against Samsung's biopharmaceutical arm Samsung Bioepis.

More features

Gilead awarded $30m over counterfeit HIV drug scheme
EPO invalidates human milk patent after Nestle opposition
Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic